Skip to main content
. 2019 Jan 30;6:9. doi: 10.3389/fmed.2019.00009

Figure 3.

Figure 3

A beta-arretin-biased agonist targets the AT1-B2 heteromer and promotes AT1-B2 down-regulation (right). The unbiased AT1 antagonist does not promote AT1-B2 down-regulation (left).